

CARBOPLATIN

Used first-line as adjuvant treatment, and also for relapsed ovarian cancer, in patients not fit enough for doublet chemotherapy

Drugs/Dosage: Carboplatin AUC 5 IV D1

N.B. Dose of AUC 6 should be considered in the following situations:

- a) patient young, fit & EDTA > 50ml/min
- b) Cockcroft and Gault formula predicts GFR > 60ml/min and fit patient. Adjust to AUC 5 once EDTA available, unless patient fits criteria in a)

Carboplatin dose should be calculated using the Calvert Formula:

$$\text{Dose} = \text{Target AUC} \times (25 + \text{GFR})$$

Cycle 1 may be given using the Cockcroft and Gault formula to predict creatinine clearance if the EDTA is not yet available. When using C&G, a “cap” of 125 ml/min should be used for carboplatin dose calculations.

Carboplatin dose should be re-calculated using the EDTA result for subsequent cycles (do not “cap”). EDTA should only be repeated if there is a 30% change in serum creatinine.

Administration: in 250ml 5% glucose over 30 – 60 minutes

Frequency: 3 weekly cycle for 6 cycles

Main Toxicities: myelosuppression

Anti-emetics: highly emetogenic (but omit ondansetron in patients at risk of obstruction)

Extravasation: non vesicant

Regular Investigations: FBC Day 1
LFTs Day 1
U&Es Day 1
CA 125 Day 1
EDTA prior to 1st cycle

Comments: For patients with infusion-related reactions to carboplatin, see the Alliance Carboplatin Hypersensitivity Guidelines.

Dose Modifications

Haematological Toxicity: WBC < 2.5 x 10⁹/l
or
Neutrophils < 1.0 x 10⁹/l
or
Platelets < 75 x 10⁹/l

Delay 1 week. Repeat FBC – if within normal parameters, proceed with 100% dose.

If patient has repeated delays, consideration can be given to reducing dose to AUC 4.

Renal Impairment: If EDTA or calculated CrCl < 20ml/min, carboplatin is contra-indicated.

Reason for Update: general review; C&G cap added	Approved by Consultant: Dr A Michael
Version: 4	Approved by Lead Chemotherapy Nurse: P Deery
Supersedes: Version 3	Date: 15.6.16
Prepared by: S Taylor	Checked by: C Tucker

Reference: Calvert, A.H. et al (1989), JCO; Vol 7: 1748 – 1756

Reason for Update: general review; C&G cap added	Approved by Consultant: Dr A Michael
Version: 4	Approved by Lead Chemotherapy Nurse: P Deery
Supersedes: Version 3	Date: 15.6.16
Prepared by: S Taylor	Checked by: C Tucker